The following are side effects that have been reported by other patients while on treatment with the BCMA-targeting bispecific antibody, elranatamab. 

Cytokine Release Syndrome (CRS)

• 58% overall 
  • Grade 1: 44%
  • Grade 2: 14%
  • Grade 3: 0.5%
• The median time of onset was two days after the most recent dose
• Symptoms lasted a median of two days

Neurological Toxicity and ICANS

• 59% overall neurological toxicity 
  • Grade 3-4 neurological toxicity was reported in 7% of patients 
• ICANS reported in 3.3% of patients 
• The median time to onset was 3 days after the most recent dose 
• Symptoms lasted a median of 2 days

Infections

Elranatamab targets a protein called BCMA. Although BCMA exists on multiple myeloma cells, it can also be found on healthy plasma cells, which protect the body from infection. Therefore, when elranatamab attacks the myeloma cells, it also makes the body more susceptible to infection due to the loss of plasma cells.  

• Serious infections occurred in 42% of patients
  • 31% of the reported infections were grade 3 or 4 
  • 7% of the reported infections were fatal 

Severe infections are possible and often occur after patients have been released from the hospital, so staying vigilant for symptoms is key in properly preventing and managing infections. 

These are not all of the side effects for elranatamab. For more information, visit ELREXFIO Medication Guide